Signal Transduction and Targeted Therapy
Last updated ISSN 2059-3635
Signal Transduction and Targeted Therapy is published by Springer Nature in medicine. It is open access. The article processing charge is $3,790.
Is your paper a fit?
The surest way to know is to compare your own abstract against what this journal has actually been publishing, rather than against its aims-and-scope page. Paste your abstract and Journal Hunt will tell you how close Signal Transduction and Targeted Therapy is — and show you journals like it.
What it publishes
Recent work in Signal Transduction and Targeted Therapy concentrates on these topics, taken from its published record rather than from its own description:
- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- Cancer Immunotherapy and Biomarkers
- RNA modifications and cancer
- Immune Cell Function and Interaction
- CAR-T cell therapy research
- Epigenetics and DNA Methylation
- Immune cells in cancer
- Immunotherapy and Immune Responses
- Cancer, Hypoxia, and Metabolism
Key facts
| Publisher | Springer Nature |
|---|---|
| ISSN | 2059-3635, 2095-9907 |
| Subject area | Medicine |
| Access | Open access |
| Article processing charge | $3,790 |
| Indexed in | Web of Science — Science Citation Index Expanded · Scopus · DOAJ |
| Articles published | 2,951 |
| Publishing since | 1975 |
| Journal website | www.nature.com/sigtrans/ |
Facts come from OpenAlex, DOAJ and Wikidata and may lag the journal’s own pages. Check the publisher’s site before submitting. Indexing shown here is what is recorded, not a complete picture — about a third of journals have no indexing recorded anywhere we can read, so “not recorded” does not mean a journal is absent from Scopus or Web of Science.
Journals like Signal Transduction and Targeted Therapy
Other established journals in medicine, if this one is not the right home for your paper: